Description
There are two arms to this study. Participants will be randomized to one of the two arms. Arm A will be given orally isotretinoin; and Arm B will receive orally isotretinoin and immunotherapy. Prior to start of study drug, participants may undergo radiation therapy, tumor evaluation, bone marrow biopsy and additional radiographical studies. In rare cases where there is persistent tumor, a tumor biopsy may be required.
Eligibility
Inclusion Criteria
o Diagnosed with high risk neuroblastoma below the age of 31 years old
o Must not have progressive disease
o Appropriate performance score
o Life expectancy of at least 2 months or greater
o Must have adequate organ function